Medication, lifestyle changes best for kids with T2DM
Children and adolescents newly diagnosed with type 2 diabetes mellitus (T2DM) should be given metformin therapy and dietary and activity guidance as first-line treatments for the disease, says the...
View ArticleFDA evaluates diabetes drugs for possible increased risk of pancreatitis,...
Diabetes drugs including exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano,...
View ArticleFDA approves first SGLT2 inhibitor for T2DM
NEW DRUG REVIEW On March 29, 2013, FDA approved canagliflozin (Invokana, Janssen Pharmaceuticals, Inc.), a once-daily tablet indicated as an adjunct to diet and exercise to improve glycemic control in...
View ArticleIncreased red meat consumption linked to type 2 diabetes
Adding more than a one-half serving of red meat daily for 4 years can increase the risk of type 2 diabetes mellitus over the subsequent 4-year period, according to a report published online June 17...
View ArticleAntipsychotics increase type 2 diabetes risk for children and youth
Children and youth on antipsychotics appear to have a 3-fold increased risk for type 2 diabetes mellitus, according to a study published by JAMA Psychiatry. William V. Bobo, MD, MPH, of the Vanderbilt...
View ArticleDapagliflozin as part of triple therapy works well for T2DM
In adult patients with type 2 diabetes mellitus (T2DM) who are uncontrolled on metformin and sulfonylurea, dapagliflozin can be added to help improve HbA1c and reduce fasting plasma glucose, body...
View ArticleDiabetes screening test missing the mark?
The current recommended screening test for type 2 diabetes mellitus may be missing the diagnosis in many adolescents, according to a new study by the University of Michigan in Ann Arbor. In 2010, the...
View ArticleClik here to view.
Drugs in Perspective: Farxiga (dapagliflozin)
Antidiabetic drugs are considered to be first-line treatment options for individuals with type 1 and type 2 diabetes mellitus. It is estimated that type 2 diabetes affects about 24 million persons in...
View ArticleInsulin added to metformin for T2DM associated with increased risk of death
Patients with type 2 diabetes mellitus who received metformin and then added insulin were at higher risk of all-cause mortality than those who added a sulfonylurea, according to a report published...
View ArticleFDA drug approvals - October 2014
FDA actions in brief Dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) once-daily tablet was approved for the treatment of adults with type 2 diabetes. Xigduo XR is...
View ArticleFDA approves combo pill for adults with type 2 diabetes
FDA has approved once-daily dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with type 2 diabetes. Xigduo XR is indicated as an adjunct...
View ArticleClik here to view.
Takeda announces post hoc analysis of data from EXAMINE cardiovascular safety...
In patients with type 2 diabetes and recent acute coronary syndrome (ACS), dipeptidyl peptidase 4 (DPP-4) inhibitor alogliptin compared to placebo did not increase the risk of heart failure (HF)...
View ArticleNitrosative & oxidative stress is associated with structural changes
Take-home message: In this article, the authors present their recent study results. The study findings demonstrated, for the first time, that in vivo structural changes in ISel band and RPE are...
View ArticlePatients with uncontrolled T2DM benefit from inhaled insulin
Patients with poorly controlled type 2 diabetes (T2DM) experienced a significant decline in their HbA1c levels when adding Technosphere inhaled insulin (Afrezza, MannKind Corp.) to their current...
View ArticleClik here to view.
Wide geographic differences exist in treating diabetes
Around the world, the treatment for 3 common chronic diseases is proceeding toward more consistent use over time, especially in the first-line treatment of type 2 diabetes mellitus, according to a...
View ArticleClik here to view.
Know these barriers to reduce type 2 diabetes costs
Low levels of adherence and persistence remain barriers to reducing the costs associated with type 2 diabetes (T2D) in the United States, according to a report by IMS Institute for Healthcare...
View Article